The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

The Department of Health (DOH) on Friday, Nov. 15, announced that the Benefits Committee (BenCom) of the Philippine Health ...

EXCLUSIVE: The Industrial Injuries Advisory Council is advising ministers to offer this support to Covid victims still ...

Migori Water and Sanitation Company registered zero revenue in October, which further complicates issues for the already ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Niyondiko, N. (2024) Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature. Open Access Library Journal, 11, 1-25. doi: 10.4236/oalib.1112246 .

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14 ...

Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call ...

Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has ...